Profile data is unavailable for this security.
About the company
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company focused on redefining psychiatry by leveraging neurobiology to develop personalized and effective treatment options. The Company's Precision Psychiatry Platform measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to identify which patients are likely to respond to its product candidates. Its clinical-stage pipeline includes drug candidates in bipolar depression, major depressive disorder, treatment resistant depression (TRD), and schizophrenia, and other mental health conditions. Its product candidates include ALTO-100, ALTO-300, ALTO-207, ALTO-203, ALTO-101, ALTO-202, and ALTO-208. ALTO-100 is a first-in-class, oral small molecule believed to work through enhancing neural plasticity in the hippocampus, a brain region important for both cognition and mood. ALTO-203 is an oral small molecule histamine H3 receptor inverse agonist.
- Revenue in USD (TTM)0.00
- Net income in USD-62.26m
- Incorporated2019
- Employees76.00
- LocationAlto Neuroscience Inc650 Castro Street, Suite 450MOUNTAIN VIEW 94041United StatesUSA
- Phone+1 (773) 255-5012
- Fax+1 (302) 655-5049
- Websitehttps://www.altoneuroscience.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4D Molecular Therapeutics Inc | 120.00k | -209.18m | 476.92m | 227.00 | -- | 1.19 | -- | 3,974.36 | -3.74 | -3.74 | 0.0022 | 7.89 | 0.0002 | -- | -- | 528.63 | -40.70 | -32.02 | -43.51 | -33.96 | -- | -- | -174,314.20 | -895.24 | -- | -- | 0.00 | -- | -99.82 | -64.94 | -59.53 | -- | 3.40 | -- |
| Solid Biosciences Inc | 0.00 | -167.14m | 482.26m | 100.00 | -- | 2.21 | -- | -- | -2.49 | -2.49 | 0.00 | 2.80 | 0.00 | -- | -- | 0.00 | -68.82 | -47.92 | -78.37 | -53.98 | -- | -- | -- | -2,151.47 | -- | -- | 0.0013 | -- | -- | -- | -29.87 | -- | -31.66 | -- |
| Prothena Corporation PLC | 11.79m | -280.46m | 482.32m | 163.00 | -- | 1.64 | -- | 40.92 | -5.21 | -5.21 | 0.219 | 5.48 | 0.0249 | -- | -- | 72,306.75 | -59.18 | -14.95 | -65.99 | -16.06 | -- | -- | -2,379.59 | -89.33 | -- | -- | 0.00 | -- | 47.92 | 178.00 | 16.81 | -- | -11.70 | -- |
| ADC Therapeutics SA | 75.21m | -166.94m | 494.27m | 263.00 | -- | -- | -- | 6.57 | -1.51 | -1.51 | 0.6852 | -2.11 | 0.2355 | 0.3207 | 3.20 | 285,965.80 | -52.26 | -45.95 | -65.58 | -53.58 | 92.73 | -- | -221.97 | -263.96 | 4.34 | -2.91 | 2.10 | -- | 1.84 | 97.79 | 34.25 | -- | -16.59 | -- |
| Keros Therapeutics Inc | 246.72m | 64.45m | 505.13m | 82.00 | 10.74 | 0.9575 | 7.67 | 2.05 | 1.54 | 1.54 | 6.07 | 17.32 | 0.3732 | -- | 127.17 | 1,459,870.00 | 9.75 | -36.26 | 10.16 | -38.17 | -- | -- | 26.12 | -2,307.89 | -- | -- | 0.00 | -- | 2,250.99 | -18.71 | -22.46 | -- | 48.10 | -- |
| Altimmune Inc | 20.00k | -83.92m | 511.14m | 59.00 | -- | 2.33 | -- | 25,556.81 | -1.07 | -1.07 | 0.0003 | 1.94 | 0.0001 | -- | 0.0314 | 338.98 | -45.82 | -42.36 | -48.64 | -45.46 | -- | -- | -419,575.00 | -3,193.88 | -- | -- | 0.0722 | -- | -95.31 | -67.83 | -7.48 | -- | -- | -- |
| Alto Neuroscience Inc | 0.00 | -62.26m | 524.71m | 76.00 | -- | 4.11 | -- | -- | -2.31 | -2.31 | 0.00 | 4.11 | 0.00 | -- | -- | 0.00 | -36.77 | -- | -39.46 | -- | -- | -- | -- | -- | -- | -- | 0.1675 | -- | -- | -- | -69.21 | -- | -- | -- |
| Neumora Therapeutics Inc | 0.00 | -236.30m | 527.34m | 95.00 | -- | 3.92 | -- | -- | -1.46 | -1.46 | 0.00 | 0.8161 | 0.00 | -- | -- | 0.00 | -89.11 | -55.45 | -99.96 | -58.77 | -- | -- | -- | -- | -- | -- | 0.1289 | -- | -- | -- | -3.33 | -- | -- | -- |
| Contineum Therapeutics Inc | 0.00 | -59.39m | 527.49m | 41.00 | -- | 2.33 | -- | -- | -2.26 | -2.26 | 0.00 | 6.18 | 0.00 | -- | -- | 0.00 | -29.19 | -- | -30.09 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -285.99 | -- | -- | -- |
| Gossamer Bio Inc | 44.05m | -156.16m | 530.03m | 144.00 | -- | -- | -- | 12.03 | -0.6872 | -0.6872 | 0.1939 | -0.356 | 0.1574 | -- | 5.57 | 305,909.70 | -55.80 | -51.30 | -69.95 | -58.28 | -- | -- | -354.50 | -822.21 | -- | -15.04 | 1.71 | -- | -- | -- | 68.56 | -- | -- | -- |
| Vor Biopharma Inc | 0.00 | -2.45bn | 530.62m | 159.00 | -- | -- | -- | -- | -386.85 | -386.85 | 0.00 | -246.54 | 0.00 | -- | -- | 0.00 | -1,676.47 | -49.21 | -1,891.22 | -52.72 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.8052 | -- | -21.08 | -- |
| Ginkgo Bioworks Holdings Inc | 180.61m | -339.55m | 535.01m | 834.00 | -- | 0.9432 | -- | 2.96 | -6.22 | -6.22 | 3.31 | 9.85 | 0.1353 | -- | 7.80 | 216,554.00 | -25.43 | -68.97 | -27.83 | -75.53 | 72.71 | 66.73 | -188.00 | -409.12 | -- | -- | 0.00 | -- | -9.71 | 33.18 | 38.73 | -- | 23.00 | -- |
| Perspective Therapeutics Inc | 1.08m | -106.31m | 535.40m | 138.00 | -- | 1.44 | -- | 498.04 | -1.46 | -1.46 | 0.0147 | 3.26 | 0.0031 | -- | 5.43 | 7,789.86 | -31.00 | -- | -33.37 | -- | -- | -- | -9,889.68 | -- | -- | -- | 0.0067 | -- | 1.39 | -- | -109.13 | -- | -- | -- |
| Lyell Immunopharma Inc | 41.00k | -325.66m | 548.94m | 300.00 | -- | 1.51 | -- | 13,388.87 | -22.26 | -22.26 | 0.0027 | 17.06 | 0.00008 | -- | -- | 136.67 | -63.41 | -28.62 | -67.72 | -30.08 | -- | -- | -794,292.70 | -1,176.84 | -- | -- | 0.00 | -- | -53.08 | -37.83 | -46.18 | -- | 14.67 | -- |
| Compass Pathways PLC (ADR) | 0.00 | -237.32m | 557.86m | 166.00 | -- | 14.84 | -- | -- | -2.68 | -2.68 | 0.00 | 0.3916 | 0.00 | -- | -- | 0.00 | -94.37 | -45.17 | -169.95 | -49.01 | -- | -- | -- | -- | -- | -2.19 | 0.4541 | -- | -- | -- | -30.94 | -- | -- | -- |
| Lexicon Pharmaceuticals Inc | 70.86m | -68.58m | 571.98m | 103.00 | -- | 3.96 | -- | 8.07 | -0.1894 | -0.1894 | 0.1954 | 0.3307 | 0.2689 | 1.06 | 27.10 | 688,000.00 | -26.02 | -55.75 | -29.23 | -66.32 | 99.41 | 95.36 | -96.77 | -1,103.37 | 5.63 | -6.58 | 0.3199 | -- | 2,481.48 | -37.35 | -13.15 | -- | 71.25 | -- |
Data as of Feb 13 2026. Currency figures normalised to Alto Neuroscience Inc's reporting currency: US Dollar USD
54.28%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Alpha Wave Global LPas of 31 Dec 2025 | 3.71m | 11.94% |
| Commodore Capital LPas of 20 Oct 2025 | 3.19m | 10.27% |
| Point72 Asset Management LPas of 30 Sep 2025 | 2.00m | 6.44% |
| Perceptive Advisors LLCas of 03 Oct 2025 | 1.99m | 6.40% |
| Armistice Capital LLCas of 30 Sep 2025 | 1.64m | 5.27% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 1.20m | 3.85% |
| Franklin Advisers, Inc.as of 31 Dec 2025 | 1.12m | 3.60% |
| Vestal Point Capital LPas of 30 Sep 2025 | 950.00k | 3.06% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 597.38k | 1.92% |
| Alkeon Capital Management LLCas of 30 Sep 2025 | 477.10k | 1.54% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
